Should fenofibrate be continued perioperatively in a patient undergoing fistulectomy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Should Fenofibrate Be Continued Perioperatively for Fistulectomy?

Fenofibrate should be discontinued prior to fistulectomy and withheld during the perioperative period, then restarted once wound healing is complete and there is no evidence of infection.

Rationale for Discontinuation

The ACC/AHA explicitly identifies the perioperative period as an increased risk state for statin-associated myopathy, and this same guidance extends to fibrates, which carry even higher myopathy risk than statins. 1 The guideline specifically notes that "in several instances, myopathy has developed when patients were continued on statin therapy during hospitalization for major surgery" and recommends it is "prudent to withhold statins during such periods." 1 Fibrates, particularly gemfibrozil but other fibrates including fenofibrate, are explicitly listed as higher-risk agents for myopathy in the perioperative setting. 1

The combination of fibrates with statins during the perioperative period substantially increases myopathy risk, and even fibrate monotherapy poses elevated risk during surgical stress states. 1, 2 The 2014 ACC/AHA cholesterol guidelines document that fenofibrate-simvastatin combination therapy was associated with increased ALT elevations and creatinine increases compared to simvastatin alone. 2

Timing of Discontinuation and Resumption

Discontinue fenofibrate at least 3-5 days before the scheduled fistulectomy. This timing allows for drug clearance while minimizing the risk of perioperative complications. 1 The FDA label does not specify a perioperative washout period, but given the drug's lipophilic properties and tissue distribution, a minimum 3-day discontinuation is prudent. 3

Resume fenofibrate only after the surgical wound demonstrates complete healing, all sutures are removed, there is no swelling, erythema, or drainage, and no evidence of surgical site or systemic infection exists. 4 For a fistulectomy, this typically means waiting 10-14 days postoperatively, though individual wound healing may vary. 4

Risk-Benefit Considerations

The short-term discontinuation of fenofibrate (1-2 weeks total) poses minimal cardiovascular risk, whereas continuing it perioperatively increases the risk of myopathy, rhabdomyolysis, and potential acute kidney injury. 1, 5 The Canadian Cardiovascular Society guidelines note that fibrates can cause 15-20% increases in plasma creatinine, with more significant increases possible in patients with underlying renal disease. 5

For patients with severe hypertriglyceridemia (>500 mg/dL), the risk of acute pancreatitis from brief fenofibrate discontinuation must be weighed against perioperative myopathy risk. 3 However, for elective procedures like fistulectomy, optimizing triglyceride control before surgery through dietary modification and ensuring levels are <500 mg/dL prior to planned discontinuation is the appropriate strategy. 6

Special Monitoring Considerations

If the patient develops muscle soreness, tenderness, or pain perioperatively, immediately measure creatine kinase (CK) levels and compare to baseline. 1 Discontinue fenofibrate if CK exceeds 10 times the upper limit of normal in the presence of muscle symptoms. 1

Monitor renal function closely when restarting fenofibrate postoperatively, as the drug commonly causes creatinine elevations of 15-20%. 5 The FDA label specifies that fenofibrate should be avoided in severe renal impairment and used cautiously in mild-to-moderate renal dysfunction. 3

Common Pitfalls to Avoid

  • Do not continue fenofibrate "because the surgery is minor." The ACC/AHA guidance on perioperative fibrate risk applies to all surgical procedures, not just major operations. 1

  • Do not restart fenofibrate at the first postoperative visit if wound healing is incomplete or infection is suspected. Wait for objective evidence of complete healing. 4

  • Do not combine fenofibrate with gemfibrozil at any time, as gemfibrozil markedly increases myopathy risk and should never be used with statins. 1, 6

  • Do not substitute over-the-counter niacin for fenofibrate during the perioperative period, as unregulated niacin formulations carry severe hepatotoxicity risk. 6

References

6
Guideline

Management of Severe Hypertriglyceridemia (Triglycerides ≥ 600 mg/dL) with Fenofibrate‑Induced Anal Pruritus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

When and how should fenofibrate be initiated, including dosing, indications, contraindications, and monitoring?
What are the differences between micro‑ionized (micronised) fenofibrate and non‑micro‑ionized fenofibrate in terms of absorption, dosing, and adverse effects?
Can fenofibrate cause muscle aches and affect thyroid function?
Can fenofibrate cause anxiety?
Should I start fenofibrate?
In a patient whose automatic blood pressure cuff shows high readings but manual auscultation reveals faint Korotkoff sounds at approximately 190 mm Hg and clearer sounds at about 140/80 mm Hg, with no aortic stenosis on echocardiogram, what does this indicate?
What is the appropriate management for a 61-year-old woman with total cholesterol 209 mg/dL, triglycerides 158 mg/dL, HDL cholesterol 57 mg/dL, VLDL cholesterol 28 mg/dL, and LDL cholesterol 124 mg/dL?
What is the appropriate evaluation and management for a 13‑year‑old who experienced a syncopal episode?
In a 79-year-old man presenting with shoulder and neck pain, sinus pressure above and below the eyes, left lower back pain worsened by deep inspiration, hypothermia, hypertension, and warm extremities, what emergent diagnosis should be considered and what immediate management is indicated?
Why is vasopressin contraindicated in local anesthetic systemic toxicity (LAST)?
A female patient started on Concerta (methylphenidate) 18 mg extended‑release two days ago and has not noticed any effect; how long should we wait before considering a dose increase?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.